Don't overestimate your knowledge in the stock market

Published 01-MAY-2020 12:14 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

There is an old saying that you don’t know what you don’t know. In my experience, over the past few decades I have found there is one thing in common with both traders and investors and that is many overestimate their level of knowledge and competency when it comes to the stock market.

According to many surveys conducted by the ASX, it is common to find around 50 per cent of adult Australians believe they are very knowledgeable or somewhat knowledgeable when it comes to investing in shares. But given that investors have repeatedly made knee jerk reactions over the past two months out of fear and, at times, greed, it is for this reason why I believe investors overestimate their level of knowledge.

That said, the recent market conditions have caused many traders and investors to question whether they are as knowledgeable as they think they are. As Albert Einstein once said, education is the progressive realisation of our ignorance and no doubt, many would agree that over the past few months the stock market has taught them a lesson or two in how much they do not know.

Unfortunately, many will not learn and are doomed to repeat the mistakes of the past. History shows that time and time again people repeat their mistakes and end up throwing their money at the share market with little or no knowledge in the hope they will profit believing it will be different this time.

In the light of the GFC and the current market conditions, and how many have reacted to these events, I believe this proves how much Australians overestimate their abilities. This is often referred to as cognitive bias, whereby we believe we are better than we actually are, and the alarming thing is that we do not know that we are not very good or knowledgeable. Unfortunately, this means that investors operate under a false sense of security, which leads to overconfidence and mistakes in judgement.

Investing in the stock market is quite easy because it really comes down to following some simple rules but that is the key that most are missing.

Most don’t know which rules to follow and those that follow the masses end up losing money or breaking even at best.

As the old saying goes, your education will cost you one way or another and it’s your choice how much you pay.

Right now is the perfect time to educate yourself so that you do not repeat the mistakes of the past.

Dale Gillham is Chief Analyst at Wealth Within and international bestselling author of How to Beat the Managed Funds by 20%. He is also the author of Accelerate Your Wealth—It’s Your Money, Your Choice, which is available in bookstores and online at www.wealthwithin.com.au



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X